Show threadTumorBoardTuesdayDec 16, 2022

4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214

Show threadTumorBoardTuesdayDec 13, 2022
12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite
Show threadTumorBoardTuesdayDec 13, 2022

5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214

💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC

TumorBoardTuesdayDec 12, 2022

#TumorBoardTuesday has 𝐩𝐫𝐨𝐦𝐢𝐬𝐞𝐝 you a full week with a GU program 𝑒𝑎𝑐ℎ night!

🧗Strap on your climbing gear for 8pm ET 𝘛𝘖𝘕𝘐𝘎𝘏𝘛 for a #RenalCell tweetorial featuring @brian_rini @katy_beckermann @shilpaonc!

🆓#CME @BonumCe🔗http://bit.ly/3VDaK81
#KEYNOTE426

RCC Tweetorial — Current Activities

In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Renal Cell Carcinoma (RCC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit

Current Activities